Health News Releases

  • Today April 9
May 10, 2019 13:16
Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes
Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the
May 10, 2019 09:27
U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a
May 09, 2019 10:24
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”)
May 08, 2019 09:20
Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss vers
May 03, 2019 16:40
Apax Funds, CPPIB and PSP Investments Agree to Sell Acelity and its KCI Subsidiaries to 3M for $6.725 Billion
A consortium comprised of funds advised by Apax Partners (the “Apax Funds”), together with Canada Pension Plan Investment Board (“CPPIB”) and the Public Sector Pension Investment Board (“PSP Investmen
April 30, 2019 17:30
Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial
Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark p
April 30, 2019 15:00
tHIS 2019 to Shape Future Health Science and Technology With Expanded Exhibition Scale in Shanghai and Hangzhou
The Health Industry Summit (tHIS) 2019, organized by Reed Sinopharm, will scale up with a total exhibition area of 400,000m2. For the first time, it will adopt the “Two Cities One Show” mode - to be l
April 30, 2019 14:00
Hospitals in Taiwan Make a Commitment to Eliminate Preventable Patient Harm & Death in Hospitals
The Patient Safety Movement Foundation (PSMF) and the Taiwan Patient Safety Culture Club (TPSCC) announced today that 4 hospitals and 1 healthcare organization made a public commitment to helping elim
April 30, 2019 11:50
Masimo Announces First CE-marked Third-party Masimo Open Connect® Module for the Root® Patient Monitoring and Connectivity Hub
Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI®) module for the Masimo Root® Patient Monitoring and Connectivity Hub
April 29, 2019 09:45
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA
April 25, 2019 17:10
USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations
Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$
April 24, 2019 18:05
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019
Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet m
April 24, 2019 17:30
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™
Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pha
April 24, 2019 17:30
Aptorum Group establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and unmet Diseases
Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and
April 23, 2019 13:50
Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto™ Intravascular Imaging System
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FD
April 23, 2019 00:00
Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer
Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
April 19, 2019 13:30
KCI Files Registration Statement for Proposed Initial Public Offering
Acelity announced today that its affiliate, KCI Holdings, Inc. (“KCI”), filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”), relating to a proposed init
April 17, 2019 18:00
Financial year 2018: Boehringer Ingelheim grows and invests
The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sa
April 17, 2019 16:55
Acelity L.P. Inc. Announces New Senior Leadership Appointments
Acelity today announced Gaurav Agarwal, Chief Commercial Officer, has been promoted to the position of President and Chief Operating Officer. Additionally, Rohit Kashyap, President of the Americas, ha
April 17, 2019 13:10
CORRECTING and REPLACING SpeeDx and Cepheid Announce Test Partnership
First sentence, seventh paragraph of release dated April 16, 2019 should read: “Currently, there is no FDA-cleared molecular diagnostic test for the combined detection of M. genitalium and macrolide r
April 17, 2019 11:30
New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry
Masimo (NASDAQ: MASI) announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure c
April 17, 2019 08:00
French Biotech CellVax is Now Able to Propose Preclinical Studies in Large Animals
Thanks to this strategic partnership, CellVax can now respond to the strong demand for optimal selection of models that represent the human disease best and is able to offer preclinical studies in lar
April 15, 2019 16:40
Independent large real-world study comparing NOACs in AF-patients
The results from an independent retrospective comparative study, published in January 2019 in the American Journal of Medicine, showed that dabigatran was associated with a more favourable benefit-har
April 15, 2019 16:35
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim has acquired a minority stake in SoundTalks NV, a Belgian company. SoundTalks NV has developed a digital monitoring tool that seeks to improve the healthcare of pigs and helps far
April 15, 2019 09:45
New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® trial in a subgroup of 2,250 people with type 2 diabet
25 per page50 per page75 per page100 per page